• FOLLOW
SPANISH

CENTRO DE INVESTIGACION DEL CANCER

  1. Concedido nuevo proyecto de investigación sobre tratamiento y diagnóstico de la Covid-19

    Actualidad

    Concedido nuevo proyecto de investigación sobre tratamiento y diagnóstico de la Covid-19

    READ MORE
  2. “Utiliza la fuerza”: un nuevo mecanismo que determina la migración y especialización celular a través del control de la textura

    Actualidad

    “Utiliza la fuerza”: un nuevo mecanismo que determina la migración y especialización celular a través del control de la textura

    READ MORE
  3. Protocolo gradual de reincorporación

    Actualidad

    Protocolo gradual de reincorporación

    READ MORE
  4. Nuevo proyecto para identificar factores de riesgo de infección grave e infectados por SARS-CoV-2

    Actualidad

    Nuevo proyecto para identificar factores de riesgo de infección grave e infectados por SARS-CoV-2

    READ MORE
  5. Scientific Seminar Series (2019-2020)

    Actualidad

    Scientific Seminar Series (2019-2020)

    READ MORE

    meetings

Marina Mendiburu-Eliçabe Garganta

Identification of Differentially Expressed Genes and Network Analysis in the search of potential molecular signatures associated with breast cancer

16/07/2020
Marina Mendiburu-Eliçabe Garganta
Centro de Investigación del Cáncer (CIC-IBMCC), Salamanca.,

READ MORE

PROGRAMA DE SEMINARIOS CIENTÍFICOS 19-20

CURSO 2019-2020

26/09/2019
PROGRAMA DE SEMINARIOS CIENTÍFICOS 19-20
Centro de Investigación del Cáncer (CIC-IBMCC), Salamanca,

READ MORE

Papers

VRK1 (Y213H) homozygous mutant impairs Cajal bodies in a hereditary case of distal motor neuropathy.
Marcos AT, Martín-Doncel E, Morejón-García P, Marcos-Alcalde I, Gómez-Puertas P, Segura-Puimedon M, Armengol L, Navarro-Pando JM, Lazo PA,
Ann Clin Transl Neurol;2020-May;2328-9503;10.1002/;32365420

Emerging roles of novel small non-coding regulatory RNAs in immunity and cancer.
Rosace D, López J, Blanco S,
RNA Biol;2020-Mar;1555-8584;10.1080/;32186461

Novel Dominant KCNQ2 Exon 7 Partial In-Frame Duplication in a Complex Epileptic and Neurodevelopmental Delay Syndrome.
Lazo PA, García JL, Gómez-Puertas P, Marcos-Alcalde I, Arjona C, Villarroel A, González-Sarmiento R, Fons C,
Int J Mol Sci;2020-Jun;1422-0067;E4447;32585800

Identification of distinct maturation steps involved in human 40S ribosomal subunit biosynthesis.
Nieto B, Gaspar SG, Moriggi G, Pestov DG, Bustelo XR, Dosil M,
Nat Commun;2020-Jan;2041-1723;10.1038/;31919354

Securin-independent regulation of separase by checkpoint-induced shugoshin-MAD2.
Hellmuth S, Gomez-H L, Pendas AM, Stemmann O,
Nature;2020-04;1476-4687;10.1038/;32322060

Working on Genomic Stability: From the S-Phase to Mitosis.
Ovejero S, Bueno A, Sacristán MP,
Genes (Basel);2020-02;2073-4425;E225;32093406

VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor sy
Martín-Doncel E, Rojas AM, Cantarero L, Lazo PA,
Sci Rep;2019-Sep;2045-2322;10.1038/;31527692

LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S, Ramirez-Labrada A, Aumann S, Lu X, Weich N, Santiago G, Cortizas EM, Sharabi E, Zhang Y, Sánchez-García I, Gentles AJ, Roberts E, Bilbao-Cortes D, Vega F, Chapman JR, Verdun RE, Lossos IS,
Cancer Cell;2019-Sep;1878-3686;S1535-61;31447348

Frontline Science: TNF-α and GM-CSF1 priming augments the role of SOS1/2 in driving activation of Ras, PI3K-γ, and neutrophil proinflammatory response
Suire S, Baltanás FC, Segonds-Pichon A, Davidson K, Santos E, Hawkins PT, Stephens LR,
J. Leukoc. Biol.;2019-Oct;1938-3673;10.1002/;30720883

PCNA Deubiquitylases Control DNA Damage Bypass at Replication Forks.
Álvarez V, Frattini C, Sacristán MP*, Gallego-Sánchez A, Bermejo R, Bueno A,
Cell Rep;2019-Oct;2211-1247;S2211-12;31665643

Pol5 is an essential ribosome biogenesis factor required for 60S ribosomal subunit maturation in .
Ramos-Sáenz A, González-Álvarez D, Rodríguez-Galán O, Rodríguez-Gil A, Gaspar SG, Villalobo E, Dosil M, de la Cruz J,
RNA;2019-Nov;1469-9001;10.1261/;31413149

Concomitant deletion of HRAS and NRAS leads to pulmonary immaturity, respiratory failure and neonatal death in mice.
Fuentes-Mateos R, Jimeno D, Gomez C, Calzada N, Fernandez-Medarde A, Santos E,
Cell Death Dis;2019-Nov;2041-4889;10.1038/;31685810

Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase.
Campillo-Marcos I, Lazo PA,
J. Exp. Clin. Cancer Res.;2019-May;1756-9966;10.1186/;31101118

Cytosine-5 RNA methylation links protein synthesis to cell metabolism.
Gkatza NA, Castro C, Harvey RF, Heiß M, Popis MC, Blanco S, Bornelöv S, Sajini AA, Gleeson JG, Griffin JL, West JA, Kellner S, Willis AE, Dietmann S, Frye M,
PLoS Biol.;2019-Jun;1545-7885;10.1371/;31199786

Novel ETV6-RUNX1 Mouse Model to Study the Role of ELF-MF in Childhood B-Acute Lymphoblastic Leukemia: a Pilot Study.
Campos-Sánchez E, Vicente-Dueñas C, Rodríguez-Hernández G, Capstick M, Kuster N, Dasenbrock C, Sánchez-García I, Cobaleda C,
Bioelectromagnetics;2019-Jul;1521-186X;10.1002/;31157932

last announcements

CONTRATO DE DOCTOR PARA SU INCORPORACIÓN AL LABORATORIO DE EPITRANSCRITÓMICA Y CÁNCER DEL CIC DE SALAMANCA

READ MORE

CONTRATO DE DOCTOR PARA SU INCORPORACIÓN AL LABORATORIO DE EPITRANSCRITÓMICA Y CÁNCER DEL CIC DE SALAMANCA

13/07/20

          

 

 

 

SE CONVOCA UN CONTRATO DE DOCTOR PARA SU INCORPORACIÓN AL LABORATORIO DE EPITRANSCRITÓMICA Y CÁNCER DEL CIC DE SALAMANCA, financiada por la Convocatoria de Ayudas destinadas a financiar planes estratégicos y programas estratégicos de investigación, ejecutados por las estructuras de investigación de excelencia, en el marco de la Estrategia regional de investigación e innovación, para una especialización inteligente (RIS3) de Castilla y León 2014-2020, cofinanciadas por la Consejería de Educación de la Junta de Castilla y León y el Fondo Europeo de Desarrollo Regional (Código  CLC-2017-01). REF: 20-7-SBDOC

 

Postdoctoral contract for 11 months available in the lab of Epitranscriptomics and cancer, led by Dr S Blanco, at Centre for Cancer Research (CIC) in Salamanca, Spain (http://www.cicancer.org/es/investigador/46/dra-sandrablanco-benavente).

 

We are looking for a highly motivated and enthusiastic candidate with interest in cancer biology, tumour microenvironment, immune-oncology, epitranscriptomics and research with potential clinical impact.

 

Many factors regulate the propensity of cancer cells to metastasise or immune cells to promote or repress tumour development. Recognition of the mechanisms that mediate key aspects of tumour progression such as EMT or factors that allow the regulation of re-education of immune cells may represent critical targets to evaluate for anti-cancer therapy. The aims of our study are ambitious and beyond the state-of-the-art aiming at defining novel concepts to develop new therapeutic strategies by integrating multidisciplinary approaches including RNA biology, cancer, immunology, omics, mouse models, clinical samples. Our studies may highlight systematically characterization of microenvironmental heterogeneity regulated by plastic cues such as RNA modifications, and show that the heterogeneity in cancer extends to epitranscriptomic variation

We offer one year postdoc salary, to work at the Centre for Cancer Research in Salamanca. The institution offers one of the best research environments in the field of cancer and cutting-edge infrastructures (Microscopy, Genomics, Bioinformatics, Proteomics). Candidates will be using cell biology techniques, microscopy, flow cytometry, next generation sequencing, organoid cultures and animal models.

  • Required Education Level: PhD
  • Skills/Qualifications: PhD in Immunology, Molecular Biology, Cancer Biology, Molecular Medicine or similar.
  • Specific Requirements: Experience in immunology and cancer.
  • Required Languages: Spanish and English
  • Required Research Experience: at least four years after completion of MSc degree.

TYPE OF CONTRACT : Temporary

JOB STATUS: Full-time

HOURS PER WEEK: 37.5

SALARY:  I Colective Agreement FICUS

ENVISAGED JOB STARTING DATE: October 2020. Negotiable.

OFFER STARTING DATE: 01.10.2020. Negotiable.

REFERENCE NUMBER:  20-7-SBDOC

Apply for the job position  REF: :20-7-SBDOC in  http://www.cicancer.org/en/grant-announcement

 

DEADLINE:          31st of August,  2020

 

 


Inscribirse DOWNLOAD PDF ×